Prostate cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• PSMA 273
• AR 16
• TP53 2
• PARP 13
• PTEN 4
• AKT 1
• BRCA2 7
• BRCA1 9
• PI3K 2
• STAT3 0
• PD-L1 6
• mTOR 1
• PD-1 13
• EZH2 7
• MYC 1
• B7-H3 8
• EGFR 2
• CTNNB1 1
• JNK 0
• ERK 0
• HIF-1 0
• VEGF 2
• BCL-2 0
• AMPK 0
• CDK4/6 4
• HER2 6
• MAPK 0
• NRF2 0
• FAK 0
• YAP 0
• PPAR 0
• IL-6 0
• STING 0
• COX-2 0
• CTLA-4 0
• DLL3 6
• GLP-1 1
• GPX4 0
• HSP90 0
• ATM 1
• HDAC 0
• IL-15 4
• METTL3 1
• BRD4 0
• HER3 2
• JAK 1
• CXCR4 0
• TROP2 3
• CD47 1
• IGF1R 0
• IL-1 0
• MET 1
• PALB2 4
• RB1 0
• TNF 0
• APOE 0
• FGFR 1
• KRAS 0
• MDM2 0
• MEK 0

24 of 3,735 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Targeting stress signaling pathways to enhance prostate cancer immunotherapy (IMMSTRESS)

  Deutsches Krebsforschungszentrum Heidelberg· Heidelberg, Germany· EU contribution €202,125· until Aug 2029

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Circulating Tumor Cell-informed RADioresponse Assessment from heme-axis signatuRes (CTC-RADAR)

  Koc University· Istanbul, Türkiye· EU contribution €398,612· until Dec 2029· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  EXPLORING THE MECHANISM OF METASTASIS/DEVELOPMENT OF NEW TESTS TO ENROLL CIRCULATING TUMOR CELLS (CTCs) INTO CLINICAL PRACTICE (CTC4CLINIC)

  Panepistimio Patron· Rio Patras, Greece· EU contribution €796,590· until Dec 2030· 7 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Exploitation of bioorthogonal click-to-release chemistry for precision cancer therapy (click-to-cure)

  Kobenhavns Universitet· Kobenhavn, Denmark· EU contribution €247,553· until Dec 2028· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  A Proteoform-Resolved Lateral Flow Immunoassay with Antibody Mimics and Engineered Release for Precise Prostate Cancer Diagnosis (PRIME)

  The Chancellor, Masters and Scholars of the University of Oxford· Oxford, United Kingdom· EU contribution €260,348· until Sept 2028

5 of 32 running projects, newest first. Listed amounts together: €116.1m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics

  NCT07406282· Bayer· Updated 10 Nov 2026

  “The PPS data source provided insufficient level of granularity on baseline characteristics, which did not allow building comparable cohorts of matching patients. Hence, the research question(s) could not be addressed”Registry text, quoted unchanged. Source

• Withdrawn

  High-resolution Intra-operative PSMA PET-CT in Prostate Cancer

  NCT06298838· IRCCS San Raffaele· Updated 6 Nov 2026

  “Difficulties in patient recruitment”Registry text, quoted unchanged. Source

• Suspended

  White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CA

  NCT04519879· City of Hope Medical Center· Updated 4 Nov 2026

  “05/26/2026 DSMC: Delinquent PMT reporting.”Registry text, quoted unchanged. Source

• Suspended

  Prostasomes as Diagnostic Tool for Prostate Cancer Detection

  NCT03694483· Hackensack Meridian Health· Updated 3 Nov 2026

  “Staffing changes, pending funding renewal”Registry text, quoted unchanged. Source

• Terminated

  Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer

  NCT05425862· Peter MacCallum Cancer Centre, Australia· Updated 2 Nov 2026

  “It was decided to stop the study due to changes in the treatment landscape.”Registry text, quoted unchanged. Source

• Withdrawn

  Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer

  NCT07090369· Peter MacCallum Cancer Centre, Australia· Updated 30 Oct 2026

  “Funding issues”Registry text, quoted unchanged. Source

• Suspended

  Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer

  NCT07219303· Fox Chase Cancer Center· Updated 29 Oct 2026

  “Pending interim analysis”Registry text, quoted unchanged. Source

• Withdrawn

  Transperineal Micro-ultrasound for the Detection of Prostate Cancer During Biopsy

  NCT07075705· Roswell Park Cancer Institute· Updated 29 Oct 2026

  “Not planning to pursue”Registry text, quoted unchanged. Source

• Withdrawn

  A Novel Augmented Reality System (ARssist) for the Assistant Surgeon in Robotic Assisted Surgery

  NCT04304079· Chinese University of Hong Kong· Updated 27 Oct 2026

  “No funding”Registry text, quoted unchanged. Source

• Terminated

  Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

  NCT02051218· Swiss Cancer Institute· Updated 23 Oct 2026

  “Board decision as by March 2026, the number of patients undergoing treatment decreased to around 50, from the total 1,380 patients enrolled in the trial. And due to price changes in medication”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma

  NCT07902921· National Cancer Institute (NCI)· Source

• Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer

  NCT07667400· National Cancer Institute (NCI)· Source

• Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer

  NCT07140900· Amgen· Source

• Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

  NCT04071236· National Cancer Institute (NCI)· Source

• National Cancer Institute "Cancer Moonshot Biobank"

  NCT04314401· National Cancer Institute (NCI)· Source

• Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department

  NCT04104529· Institut du Cancer de Montpellier - Val d'Aurelle· Source

• Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

  NCT03866382· National Cancer Institute (NCI)· Source

• Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18FDCFPyL

  NCT05588128· National Cancer Institute (NCI)· Source

• An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC

  NCT06894511· Novartis Pharmaceuticals· Source

• Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue

  NCT02594202· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 42
• Organoids 15
• Mendelian Randomization Analysis 38
• CRISPR-Cas Systems 14
• Gene Expression Profiling 153
• Sequence Analysis, RNA 11
• Whole Genome Sequencing 9
• Exome Sequencing 4
• Proteomics 47
• Metabolomics 27
• Mass Spectrometry 16
• Flow Cytometry 58
• Immunohistochemistry 120
• Liquid Biopsy 30
• Circulating Tumor DNA 32
• Xenograft Model Antitumor Assays 287
• Positron-Emission Tomography 125
• Magnetic Resonance Imaging 464
• Machine Learning 122
• Deep Learning 101
• Cohort Studies 276
• Genome-Wide Association Study 61

• Advances in Urinary Liquid Biopsy: A Review of Emerging Sensing Platforms for Early Cancer Screening and Diagnosis.

  Sensors (Basel), Oct 2026

• Uncovering the diagnostic potential of seminal fluid beyond fertility: cfDNA methylation analysis for the detection of clinically significant prostate cancer.

  PLoS One, Sept 2026

• Present status of prostate cancer diagnosis, limitations, challenges, and future endeavors.

  Ann Med, Aug 2026

• Dual Marker Co-Expressed Exosome-Based Liquid Biopsy Electrochemical Assay for Enhanced-Accuracy Diagnosis of Prostate Cancer.

  ACS Sens, Jul 2026

• Towards implementation of precision medicine biomarkers in early detection and prognostication of prostate cancer.

  Cancer Metastasis Rev, Jul 2026

• Immunoediting and precision biomarkers in prostate cancer: The emerging role of liquid biopsy, immune contexture and HLA genotype (Review).

  Int J Oncol, Jul 2026

• Pan-Cancer Liquid Biopsy and Treatment Monitoring via a Split crRNA-Activated Label-Free CRISPR/Cas12a Platform for Ultrasensitive MicroRNA Detection.

  Anal Chem, Jul 2026

• Interference of clonal hematopoiesis in cfDNA liquid biopsy testing and identification of actionable alterations in large diverse cohort of US veterans.

  Oncologist, Jul 2026

• Evolving role of biomarkers beyond prostate‑specific antigen in refining prostate cancer screening: From blood‑based tests to urinary and genetic markers (Review).

  Mol Med Rep, Jul 2026

• Inter- and intra-quartile comparison of multi-tracer PET/CT and liquid biopsy molecular markers in cancer: a futuristic perspective on evolving a "stepped care" model for individualized precision theranostics through AI/ML.

  Eur J Nucl Med Mol Imaging, Jun 2026

See which targets of this disease your abstract mentions, and go to the people working on them.